Xing L - Search Results

1

Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu.

Zhang L, Tai YT, Ho M, Xing L, Chauhan D, Gang A, Qiu L, Anderson KC. Zhang L, et al. Among authors: xing l. Blood Cancer J. 2017 Mar 24;7(3):e547. doi: 10.1038/bcj.2017.24. Blood Cancer J. 2017. PMID: 28338671 Free PMC article. No abstract available.

2

[Cytogenetic abnormality of chromosome 13q14 in 112 patients with multiple myeloma detected by using LSI-RB1 and LSI-D13S319 probes].

Li F, Hu LP, An G, Xu Y, Wang YY, Xing LJ, Yi SH, Xie ZQ, Qiu LG. Li F, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Aug;20(4):917-21. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012. PMID: 22931654 Chinese.

3

[Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].

Li F, Yi SH, Yu Z, Xing LJ, Xu Y, Qi JY, Zhao YZ, Li ZJ, Qiu LG. Li F, et al. Zhonghua Xue Ye Xue Za Zhi. 2013 May;34(5):383-8. doi: 10.3760/cma.j.issn.0253-2727.2013.05.002. Zhonghua Xue Ye Xue Za Zhi. 2013. PMID: 23688746 Chinese.

4

[Prognostic value of serum IL-6 in patients with multiple myeloma].

Xing LJ, Xu Y, An G, Deng SH, Sui WW, Li F, Zhou DH, Zhao YZ, Qiu LG. Xing LJ, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Dec;21(6):1492-5. doi: 10.7534/j.issn.1009-2137.2013.06.023. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013. PMID: 24370035 Chinese.

5

A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.

Liu J, Song T, Zhou W, Xing L, Wang S, Ho M, Peng Z, Tai YT, Hideshima T, Anderson KC, Cang Y. Liu J, et al. Among authors: xing l. Leukemia. 2019 Jan;33(1):171-180. doi: 10.1038/s41375-018-0205-y. Epub 2018 Jul 19. Leukemia. 2019. PMID: 30026574 Free PMC article.

6

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.

Tai YT, Lin L, Xing L, Cho SF, Yu T, Acharya C, Wen K, Hsieh PA, Dulos J, van Elsas A, Munshi N, Richardson P, Anderson KC. Tai YT, et al. Among authors: xing l. Leukemia. 2019 Feb;33(2):426-438. doi: 10.1038/s41375-018-0242-6. Epub 2018 Aug 22. Leukemia. 2019. PMID: 30135465 Free PMC article.

7

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.

Cho SF, Lin L, Xing L, Yu T, Wen K, Anderson KC, Tai YT. Cho SF, et al. Among authors: xing l. Antibodies (Basel). 2017 Nov 14;6(4):18. doi: 10.3390/antib6040018. Antibodies (Basel). 2017. PMID: 31548533 Free PMC article. Review.

8

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.

Xing L, Lin L, Yu T, Li Y, Cho SF, Liu J, Wen K, Hsieh PA, Kinneer K, Munshi N, Anderson KC, Tai YT. Xing L, et al. Leukemia. 2020 Aug;34(8):2150-2162. doi: 10.1038/s41375-020-0745-9. Epub 2020 Feb 14. Leukemia. 2020. PMID: 32060401 Free PMC article.

9

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.

Cho SF, Lin L, Xing L, Li Y, Yu T, Anderson KC, Tai YT. Cho SF, et al. Among authors: xing l. Cancers (Basel). 2020 Jun 5;12(6):1473. doi: 10.3390/cancers12061473. Cancers (Basel). 2020. PMID: 32516895 Free PMC article. Review.

10

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.

Lin L, Cho SF, Xing L, Wen K, Li Y, Yu T, Hsieh PA, Chen H, Kurtoglu M, Zhang Y, Andrew Stewart C, Munshi N, Anderson KC, Tai YT. Lin L, et al. Among authors: xing l. Leukemia. 2021 Mar;35(3):752-763. doi: 10.1038/s41375-020-0951-5. Epub 2020 Jul 6. Leukemia. 2021. PMID: 32632095 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,939 results

Search Page

Filters